alpha galactosidase/atrophy

A hivatkozás a vágólapra kerül

Válasszon rendezési típust

Oldal 1 tól től 59 eredmények

Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

BACKGROUND Mutations in the gene for alpha-galactosidase A result in Fabry disease, a rare, X-linked lysosomal storage disorder characterized by a loss of alpha-galactosidase A enzymatic activity. The resultant accumulation of glycosphingolipids throughout the body leads to widespread vasculopathy

Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

We report a case of kidney transplantation from mother to son, both of whom were likely to have had an unrecognized renal variant phenotype of Fabry disease. The patient was a 54-year-old man, with an unknown primary cause of end stage renal disease. He had no notable past medical history, other

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Fabry disease is an X-linked genetic disorder characterized by deficient activity of α-galactosidase A (GLA) and accumulation of glycolipids, and various GLA gene mutations lead to a wide range of clinical phenotypes from the classic form to the later-onset one. To investigate the biochemical

[A novel alpha-galactosidase from Arthrobacter sp. GN14 isolated from Grus nigricollis feces: gene cloning, heterologous expression and characterization].

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

OBJECTIVE Cloning and heterologously expressing the alpha-galactosidase gene (agaAGN14) from Arthrobacter sp. GN14 isolated from feces of black-neck crane (Grus nigricollis). METHODS The full-length agaAGN14 was cloned based on degenerate PCR and GC TAIL-PCR (thermal asymmetric interlaced PCR),

Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Fabry disease is an X-linked disorder caused by a deficiency of the lysosomal alpha-galactosidase A [EC 3.2.1.22]. The molecular diagnosis of Fabry disease is important for genotype/phenotype correlation, pre-natal or early diagnosis, and detection of carrier status. Although more than 200 genotypes

Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

The current treatment of Fabry disease by enzyme replacement therapy with commercially available recombinant human α-Galactosidase A shows a continuous deterioration of the disease patients. Human recombinant α-Galactosidase A is a homodimer with noncovalently bound subunits and is expressed in the

A thermostable alpha-galactosidase from Lactobacillus fermentum CRL722: genetic characterization and main properties.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Alpha-galactosidase (alpha-Gal) enzyme, which is encoded by the melA gene hydrolyzes alpha-1,6 galactoside linkages found in sugars, such as raffinose and stachyose. These alpha-galacto-oligosaccharides (alpha-GOS), which are found in large quantities in vegetables, such as soy, can cause

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Fabry disease is an X-linked lysosomal storage disease afflicting 1 in 40,000 males with chronic pain, vascular degeneration, cardiac impairment, and other symptoms. Deficiency in the lysosomal enzyme alpha-galactosidase (alpha-GAL) causes an accumulation of its substrate, which ultimately leads to

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

BACKGROUND Fabry disease is a rare and progressive X-linked inherited disorder of glycosphingolipid metabolism that is due to deficient or absent lysosomal a-galactosidase A activity. Among its other associated signs and symptoms, patients present with renal failure and proteinuria, which are

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

BACKGROUND A high incidence of GLA IVS4+919 G>A mutation in patients with Fabry disease of the later-onset cardiac phenotype, has been reported in Taiwan. However, suitable biomarkers or potential therapeutic surrogates for Fabry cardiomyopathy (FC) in such patients under enzyme replacement

[Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies].

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

BACKGROUND Anderson-Fabry disease (AFD) is a multiorgan X-linked lysosomal storage disease that particularly affects the heart, kidneys, and cerebrovascular system. Current treatment is with enzyme replacement therapy (ERT), using either beta-galactosidase ('Fabrazyme') or alpha-galactosidase

Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Fabry disease is an X-linked lysosomal storage disorder caused by inherited deficiency of the enzyme a-galactosidase A. Enzyme replacement treatment using agalsidase alfa significantly reduces pain, improves cardiac function and quality of life, and slows renal deterioration. Nevertheless, it is a

Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Mucopolysaccharidosis type VII (MPS VII) is a lysosomal storage disease caused by beta-glucuronidase (GUSB) deficiency. This disease exhibits a broad spectrum of clinical signs including skeletal dysplasia, retinal degeneration, cognitive deficits and hearing impairment. Sustained, high-level

The co-existence of Fabry and celiac diseases: a case report.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

We present a patient with Fabry disease with remarkable diagnostic findings and gluten-sensitive enteropathy. An 11-year-old girl was admitted to hospital with weight loss, anorexia, nausea, vomiting, flank pain, acroparesthesia, and painful extremities. Her mother had end-stage renal failure

HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro.

Csak regisztrált felhasználók fordíthatnak cikkeket

Belépés Regisztrálás

Lentiviral vectors are prime candidate vectors for gene transfer into dividing and non-dividing cells, including neuronal cells and stem cells. For safety, HIV-2 lentiviral vectors may be better suited for gene transfer in humans than HIV-1 lentiviral vectors. HIV-2 vectors cross-packaged in HIV-1

Előző
1
2
3
4
Következő

Csatlakozzon
facebook oldalunkhoz

Herbal & Natural Medicine

A legteljesebb gyógynövény-adatbázis, amelyet a tudomány támogat

Működik 55 nyelven
A tudomány által támogatott gyógynövényes kúrák
Gyógynövények felismerése kép alapján
Interaktív GPS térkép - jelölje meg a gyógynövényeket a helyszínen (hamarosan)
Olvassa el a keresésével kapcsolatos tudományos publikációkat
Keresse meg a gyógynövényeket hatásuk szerint
Szervezze meg érdeklődését, és naprakész legyen a hírkutatással, a klinikai vizsgálatokkal és a szabadalmakkal

Írjon be egy tünetet vagy betegséget, és olvassa el azokat a gyógynövényeket, amelyek segíthetnek, beírhat egy gyógynövényt, és megtekintheti azokat a betegségeket és tüneteket, amelyek ellen használják.
* Minden információ publikált tudományos kutatáson alapul